Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs

Bibliography

• HENNESSEN W: [75 years of serum therapy]. Dtsch. Med. Wochenschr.1 (1965) 90:2181-2182.
   Google Scholar
• KOHLER G, MILSTEIN C: Continuouscultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118–129.
   PubMed Web of Science ®Google Scholar
• ••An excellent overview of therapeuticanticancer mAbs used in the clinic and in trials, and ways in which to improve their efficacy.
   Google Scholar
• GELDERMAN KA, TOMLINSON S, ROSS GD, GORTER A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol (2004) 25:158–164.
   PubMed Web of Science ®Google Scholar
• RAVETCH JV, BOLLAND S: IgG Fc receptors. Annu. Rev. Immunol (2001) 19:275–290.
   PubMed Web of Science ®Google Scholar
• SEINO J, EVELEIGH P, WARNAAR S, VAN HAARLEM LJ, VAN ES LA, DAHA MR: Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies. Clin. Exp. Immunol (1993) 94:291–296.
   PubMed Web of Science ®Google Scholar
• WALPORT MJ: Complement. First of two parts. N Engl. J. Med. (2001) 344:1058–1066.
   Google Scholar
• WALPORT MJ: Complement. Second oftwo parts. N Engl J. Med. (2001) 344:1140–1144.
   Google Scholar
• ROSS GD: Regulation of the adhesion versus cytotoxic functions of the Mac-1/ CR3/alphaMbeta2-integrin glycoprotein. Crit. Rev. Immunol (2000) 20:197–222.
   PubMed Web of Science ®Google Scholar
• •A clear review describing how to utilise CR3 for cancer immunotherapy with mAbs.
   Google Scholar
• CHRISTIANSEN J, RAJASEKARAN AK: Biological impediments to monoclonal antibody-based cancer immunotherapy. MoL Cancer Ther (2004) 3:1493–1501.
   PubMed Web of Science ®Google Scholar
• JURIANZ K, ZIEGLER S, GARCIA-SCHULER H et al.: Complement resistance of tumor cells: basal and induced mechanisms. MoL Immunol (1999) 36:929–939.
   PubMed Web of Science ®Google Scholar
• GORTER A, MERI S: Immune evasion oftumor cells using membrane-bound complement regulatory proteins. Immunol Today (1999) 20:576–582.
   PubMedGoogle Scholar
• GELDERMAN KA, BLOK VT, FLEUREN GJ, GORTER A: The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Invest. (2002) 82:483–493.
   PubMed Web of Science ®Google Scholar
• GORTER A, BLOK VT, HAASNOOT WH, ENSINK NG, DAHA MR, FLEUREN GJ: Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab. Invest. (1996) 74:1039–1049.
   PubMed Web of Science ®Google Scholar
• NIEHANS GA, CHERWITZ DL, STALEY NA, KNAPP DJ, DALMASSO AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol (1996) 149:129–142.
   PubMed Web of Science ®Google Scholar
• DONIN N, JURIANZ K, ZIPOREN L, SCHULTZ S, KIRSCHFINK M, FISHELSON Z: Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol (2003) 131:254–263.
   Google Scholar
• KOJIMA A, IWATA K, SEYA T et ell.: Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J. Immunol (1993) 151:1519–1527.
   Google Scholar
• MASAKI T, MATSUMOTO M, NAKANISHI I, YASUDA R, SEYA T: Factor I-dependent inactivation of human complement C4b of the classical pathway by C3b/C4b receptor (CR1, CD35) and membrane cofactor protein (MCP, CD46). J. Biochem. (Tokyo) (1992) 111:573–578.
   PubMed Web of Science ®Google Scholar
• DEVAUX P, CHRISTIANSEN D, FONTAINE M, GERLIER D: Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur. J. Immunol (1999) 29:815–822.
   PubMed Web of Science ®Google Scholar
• NICHOLSON-WELLER A, WANG CE: Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. (1994) 123:485–491.
   PubMed Web of Science ®Google Scholar
• SEYA T: Human regulator of complementactivation (RCA) gene family proteins and their relationship to microbial infection.Microbiol Immunol (1995) 39:295–305.
   PubMed Web of Science ®Google Scholar
• MERI S, MORGAN BP, DAVIES A et al.:Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 71:1–9.
   PubMed Web of Science ®Google Scholar
• FISHELSON Z, DONIN N, ZELL S, SCHULTZ S, KIRSCHFINK M: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. MoL Immunol (2003) 40:109–123.
   PubMed Web of Science ®Google Scholar
• GELDERMAN KA, HAKULINEN J, HAGENAARS M, KUPPEN PJ, MERI S, GORTER A: Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model. MoL Immunol (2003) 40:13–23.
   PubMed Web of Science ®Google Scholar
• BLOK VT, DAHA MR, TIJSMA O et al.:A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J. Immunol (1998) 160:3437–3443.
   PubMed Web of Science ®Google Scholar
• GELDERMAN KA, KUPPEN PJ, BRUIN W, FLEUREN GJ, GORTER A: Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur. J. Immunol (2002) 32:128–135.
   PubMed Web of Science ®Google Scholar
• MEDOF ME, WALTER El, RUTGERS JL, KNOWLES DM, NUSSENZWEIG V: Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. (1987) 165:848–864.
   PubMed Web of Science ®Google Scholar
• LI L, SPENDLOVE I, MORGAN J, DURRANT LG: CD55 is over-expressed in the tumour environment. Br. J. Cancer (2001) 84:80–86.
   PubMed Web of Science ®Google Scholar
• MATSUO S, ICHIDA S, TAKIZAWA H et al.: In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J. Exp. Med. (1994) 180:1619–1627.
   PubMed Web of Science ®Google Scholar
• TAKIZAWA H, OKADA N, OKADA H: Complement inhibitor of rat cell membrane resembling mouse Crry/p65. j Immunol (1994) 152:3032–3038.
   PubMed Web of Science ®Google Scholar
• CARAGINE TA, OKADA N, FREY AB, TOMLINSON S: A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res. (2002) 62:1110–1115.
   PubMed Web of Science ®Google Scholar
• BARANYI L, BARANJI K, TAKIZAWA H, OKADA N, OKADA H: Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. Immunology (1994) 82:522–528.
   PubMed Web of Science ®Google Scholar
• SIER CF, GELDERMAN KA, PRINS FA, GORTER A: Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int. J. Cancer (2004) 109:900–908.
   PubMed Web of Science ®Google Scholar
• SHIN ML, HANSCH G, HU VW, NICHOLSON-WELLER k Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J. Immunol. (1986) 136:1777–1782.
   PubMed Web of Science ®Google Scholar
• ZHANG HF, YU J, CHEN S, MORGAN BP, ABAGYAN R, TOMLINSON S: Identification of the individual residues that determine human CD59 species selective activity. J. Biol. Chem. (1999) 274:10969–10974.
   PubMed Web of Science ®Google Scholar
• GELDERMAN KA, KUPPEN PJ, OKADA N, FLEUREN GJ, GORTER A: Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res. (2004) 64:4366–4372.
   PubMed Web of Science ®Google Scholar
• •The first study showing effective tumour-specific inhibition of mCRPs in vivo.
   Google Scholar
• OHTA R, KONDOR N, DOHI N et al.:Mouse complement receptor-related gene y/ p65-neutralized tumor vaccine induces antitumor activity in vivo. J. Immunol (2004) 173:205–213.
   PubMed Web of Science ®Google Scholar
• IMAI M, OHTA R, OKADA N, TOMLINSON S: Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma. Int. J. Cancer (2004) 110:875–881.
   PubMed Web of Science ®Google Scholar
• MENON AG, FLEUREN GJ, ALPHENAAR EA et al.: A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer. Cancer Immunol Immunother. (2003) 52:121–126.
   PubMed Web of Science ®Google Scholar
• VELDERS MP, VAN RHIJN CM, OSKAM E, FLEUREN GJ, WARNAAR SO, LITVINOV SV: The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br. J. Cancer (1998) 78:478–483.
   PubMed Web of Science ®Google Scholar
• MENARD S, CANEVARI S, COLNAGHI MI: Hybrid antibodies in cancer diagnosis and therapy. Int. J. Biol. Markers (1989) 4:131–134.
   Google Scholar
• GORTER A. VAN DE GRIEND RJ, VAN EENDENBURG JD, HAASNOOT WH, FLEUREN GJ: Production of bi-specific monoclonal antibodies in a hollow-fibre bioreactor. Immunol Methods (1993) 161:145–150.
   PubMed Web of Science ®Google Scholar
• COCHLOVIUS B, KIPRIYANOV SM, STASSAR MJ et al.: Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J. Immuna (2000) 165:888–895.
   PubMed Web of Science ®Google Scholar
• WU H, DALEACQUA WF: Humanized antibodies and their applications. Methods (2005) 36:1–2.
   PubMed Web of Science ®Google Scholar
• MARVIN JS, ZHU Z: Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin (2005) 26:649–658.
   PubMed Web of Science ®Google Scholar
• LUM HE, MILLER M, DAVOL PA, GRABERT RC, DAVIS JB, LUM LG: Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas. Anticancer Res. (2005) 25:43–52.
   PubMed Web of Science ®Google Scholar
• LUM LG, SEN M: Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside. Acta Haematol (2001) 105:130–136.
   PubMed Web of Science ®Google Scholar
• SEN M, WANKOWSKI DM, GARLIE NK et al.: Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J. Hem atother. Stem Cell Res. (2001) 10:247–260.
   PubMedGoogle Scholar
• DA COSTA L, RENNER C, HARTMANN F, PFREUNDSCHUH M: Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease. Cancer Chemother. Pharmacol (2000) 46(Suppl.):533–536.
   Google Scholar
• BAUER S, RENNER C, JUWANA JP et al.: Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res. (2000) 59:1961–1965.
   Web of Science ®Google Scholar
• FLIEGER D, KUFER P, BEIER I, SAUERBRUCH T, SCHMIDT-WOLF IG: A bispecific single-chain antibody directed against EpCAM/ CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells. Cancer Immunol Immunother. (2000) 49:441–448.
   PubMed Web of Science ®Google Scholar
• LEWIS LD, BEELEN AP, COLE BF et al.:The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-lb in a multiple-dose Phase I study in patients with advanced cancer. Cancer Chemother. Pharmacol (2002) 49:375–384.
   PubMed Web of Science ®Google Scholar
• JAMES ND, ATHERTON PJ, JONES J, HOWIE AJ, TCHEKMEDYIAN S, CURNOW RT: A Phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br. J. Cancer (2001) 85:152–156.
   PubMed Web of Science ®Google Scholar
• VAN SCHAIJK FG, OOSTERWIJK E, MOLKENBOER-KUENEN JD et al.: Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J. Nud Med. (2005) 46:495–501.
   Web of Science ®Google Scholar
• WEISBART RH, HANSEN JE, CHAN G et al.: Antibody-mediated transduction of p53 selectively kills cancer cells. Int. J. Oncol (2004) 25:1867–1873.
   PubMed Web of Science ®Google Scholar
• WEISBART RH, WAKELIN R, CHAN G, MILLER CW, KOEFFLER PH: Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int. J. Oncol (2004) 25:1113–1118.
   PubMed Web of Science ®Google Scholar
• BALAIAN L, BALL ED: Inhibition of acutemyeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Leuk. Res. (2004) 28:821–829.
   PubMed Web of Science ®Google Scholar
• JUHL H, PETRELLA EC, CHEUNG NK, BREDEHORST R, VOGEL CW: Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology (1997) 197:444–459.
   Google Scholar
• REITER Y, FISHELSON Z: Targeting ofcomplement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. Immunol (1989) 142:2771–2777.
   Web of Science ®Google Scholar
• REITER Y, FISHELSON Z: Killing of human tumor cells by antibody C3b conjugates and human complement. Targeted Diagn. Ther. (1989) 2:119–135.
   PubMedGoogle Scholar
• GAGGAR A, SHAYAKHMETOV DM, LIEBER A: CD46 is a cellular receptor for group B adenoviruses. Nat. Med. (2003) 9:1408–1412.
   PubMed Web of Science ®Google Scholar
• HEDE K: RNA-based nanoparticle treatment shows promise in Ewing's sarcoma model. J. Nati Cancer Inst. (2005) 97:627.
   PubMed Web of Science ®Google Scholar
• HEDE K: Blocking cancer with RNA interference moves toward the clinic. J. Nati Cancer Inst. (2005) 97:626–628.
   PubMed Web of Science ®Google Scholar
• YAN J, VETVICKA V, XIA Y et ed.: Beta-glucan, a 'specific' biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor Type 3 (CD11b/CD18). J. Immunol (1999) 163:3045–3052.
   Google Scholar
• XIA Y, VETVICKA V, YAN J, HANIKYROVA M, MAYADAS T, ROSS GD: The beta-glucan-binding lectin site of mouse CR3 (CD1lb/CD 18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol (1999) 162:2281–2290.
   PubMed Web of Science ®Google Scholar
• ROSS GD, VETVICKA V, YAN J, XIA Y,VETVICKOVA J: Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology (1999) 42:61–74.
   PubMed Web of Science ®Google Scholar
• YAN J, ALLENDORF DJ, BRANDLEY B: Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin. Biol. Ther. (2005) 5:691–702.
   PubMed Web of Science ®Google Scholar
• YAN J, VETVICKA V XIA Y, HANIKYROVA M, MAYADAS TN, ROSS GD: Critical role of Kupffer cell CR3 (CD1 lb/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology (2000) 46:39–54.
   PubMed Web of Science ®Google Scholar
• HONG F, HANSEN RD, YAN J et al.: Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. (2003) 63:9023–9031.
   PubMed Web of Science ®Google Scholar
• HONG F, YAN J, BARAN JT et al.: Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models./ Immunol (2004) 173:797–806.
   PubMed Web of Science ®Google Scholar